Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients

Nephrology Dialysis Transplantation

Volumn 21, Issue SUPPL. 3, 2006, Pages

  Andrés, Vicente ^a   Castro, Claudia ^b   Campistol, Josep M ^c  

^a INSTITUTO DE BIOMEDICINA DE VALENCIA   (Spain)

^b Laboratory of Oncology   (Argentina)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Atherosclerosis; Cardioprotective; Dyslipidaemia; Everolimus; Mammalian target of rapamycin inhibitors; Proliferation signal inhibitors; Renal transplant; Sirolimus

Indexed keywords

ANTITHROMBOCYTIC AGENT; APOLIPOPROTEIN B100; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CHOLESTEROL; EVEROLIMUS; FATTY ACID BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INSULIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROLIFERATION SIGNAL INHIBITORS; RAPAMYCIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE GRAFT REJECTION; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY CONSTRICTION; CORONARY STENT; DRUG HALF LIFE; DRUG WITHDRAWAL; DYSLIPIDEMIA; GRAFT RECIPIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MOLECULAR MECHANICS; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; STEADY STATE; THROMBOSIS;

ATHEROSCLEROSIS; CELL PROLIFERATION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PROTEIN KINASES; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 33745787242     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl296     Document Type: Article

References (38)

1. Parfrey PA, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10: 1606-1615
2. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot 1975; 28: 727-732
3. Marx SO, Marks AR. Bench to bedside: The development of rapamycin and its application to stent restenosis. Circulation 2001; 104: 852-855
4. Castro C, Campistol JM, Sancho D, Sánchez-Madrid F, Casals E, Andrés V. Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1-independent pathway. Atherosclerosis 2004; 172: 31-38
5. Schuler W, Sedrani R, Cottens S et al. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36-42
6. Neumayer H-H. Introducing everolimus (Certicana®) in organ transplantation: An overview of preclinical and early clinical developments. Transplantation 2005; 79 [Suppl]: S72-S75
7. Vítko Š, Tedesco H, Eris J et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 626-635
8. Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche HU, Van Buren CT. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66: 1040-1046
9. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiactransplant recipients. N Engl J Med 2003; 349: 847-858
10. Keogh A, Richardson M, Ruygrok P et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years - a randomized clinical trial. Circulation 2004; 110: 2694-2700
11. Levy G, Moeller V, Jaffe J et al. Safety, tolerability and efficacy of everolimus in de novo liver transplant recipients: 12 and 36 month results. Liver Transplant 2006; doi:10.1002/lt.20707
12. Trotter JF, Wachs M, Bak T et al. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl 2001; 7: 343-351
13. Snell GI, Valentine VG, Vitulo P et al. Everolimus versus azathioprine in maintenance lung transplant recipients: An international, randomized, double-blind clinical trial. Am J Transplant 2006; 6: 169-177
14. Shitrit D, Rahamimov R, Gidon S et al. Use of sirolimus and low-dose calcineurin inhibitor in lung transplant recipients with renal impairment: Results of a controlled pilot study. Kidney Int 2005; 67: 1471-1475
15. Viklicky O, Zou H, Muller V, Lacha J, Szabo A, Heemann U. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation 2000; 69: 497-502
16. Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780
17. Costa RA, Lansky AJ, Mintz GS et al. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). Am J Cardiol 2005; 95: 113-116
18. Díez-Juan A, Andrés V. Coordinate control of proliferation and migration by the p27Kip1/cyclin-dependent kinase/retinoblastoma pathway in vascular smooth muscle cells and fibroblasts. Circ Res 2003; 92: 402-410
19. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005; 45: 2088-2092
20. Nebeker JR, Virmani R, Bennett CL et al. Hypersensitivity cases associated with drug-eluting coronary stents: A review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006; 47: 175-181
21. Togni M, Windecker S, Cocchia R et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 2005; 46: 231-236
22. Boots JM, Christiaans MH, van Hooff JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: Focus on the cardiovascular risk. Drugs 2004; 64: 2047-2073
23. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomized multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194-202
24. MacDonald AS. RAPAMUNE Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/ cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271-280
25. Kramer BK, Stahl R et al. Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab. Transplant Proc 2005; 37: 1601-1604
26. Morrisett JD, Abdel-Fattah G, Hoogeveen R et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002; 43: 1170-1180
27. Hoogeveen RC, Ballantyne CM, Pownall HJ et al. Effect of sirolimus on the metabolism of apoB100-containing lipoproteins in renal transplant patients. Transplantation 2001; 72: 1244-1250
28. Tur MD, Garrigue V, Vela C et al. Apolipoprotein CIII is upregulated by anticalcineurins and rapamycin: Implications in transplantation-induced dyslipidemia. Transplant Proc 2000; 32: 2783-2784
29. Liu Q-Y, Nambi P. Sirolimus upregulates aP2 expression in human monocytes and macrophages. Transplant Proc 2004; 36: 3229-3231
30. Meir KS, Leitersdorf E. Atherosclerosis in the apolipoprotein-Edeficient mouse: A decade of progress. Arterioscler Thromb Vasc Biol 2004; 24: 1006-1014
31. Elloso MM, Azrolan N, Sehgal SN et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. Am J Transplant 2003; 3: 562-569
32. Pakala R, Stabile E, Jang GJ, Clavijo L, Waksman R. Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis. J Cardiovasc Pharmacol 2005; 46: 481-486
33. Waksman R, Pakala R, Burnett MS et al. Oral rapamycin inhibits growth of atherosclerotic plaque in apoE knock-out mice. Cardiovasc Radiat Med 2003; 4: 34-38
34. Naoum JJ, Woodside KJ, Zhang S, Rychahou PG, Hunter GC. Effects of rapamycin on the arterial inflammatory response in atherosclerotic plaques in Apo-E knockout mice. Transplant Proc 2005; 37: 1880-1884
35. Naoum JJ, Zhang S, Woodside KJ et al. Aortic eNOS expression and phosphorylation in Apo-E knockout mice: Differing effects of rapamycin and simvastatin. Surgery 2004; 136: 323-328
36. Basso MD, Nambi P, Adelman SJ. Effect of sirolimus on the cholesterol content of aortic arch in ApoE knockout mice. Transplant Proc 2003; 35: 3136-3138
37. Varghese Z, Fernando R, Moorhead JF, Powis SH, Ruan XZ. Effects of sirolimus on mesangial cell cholesterol homeostasis: A novel mechanism for its action against lipid-mediated injury in renal allografts. Am J Physiol Renal Physiol 2005; 289: F43-F48
38. Bellosta S, Arnaboldi L, Canavesi P et al. Everolimus affects cholesterol homeostasis in macrophages. 7th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology. Denver, Co, USA, 27-29 April 2006.